Responsivity of the striatal dopamine system to methylphenidate: A 
within-subject I-123-β-CIT-SPECT study in male children and adolescents with 
attention-deficit/hyperactivity disorder

Aster, Hans-Christoph; Romanos, Marcel; Walitza, Susanne; Gerlach, Manfred; Mühlberger, Andreas; Rizzo, Albert; Andreatta, Marta; Hasenauer, Natalie; Hartrampf, Philipp E.; Nerlich, Kai; Reiners, Christoph; Lorenz, Reinhard; Buck, Andreas K.; Deserno, Lorenz

doi:10.3389/fpsyt.2022.804730

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Responsivity of the striatal dopamine system to methylphenidate: A within-subject I-123-β-CIT-SPECT study in male children and adolescents with attention-deficit/hyperactivity disorder

MPS-Authors

/persons/resource/persons104604

Deserno, Lorenz
Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics, University Hospital Würzburg, Germany;
Department Neurology, MPI for Human Cognitive and Brain Sciences, Max Planck Society;
Department of Psychiatry and Psychotherapy, TU Dresden, Germany;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

Aster_2022.pdf
(Publisher version), 892KB

Supplementary Material (public)

There is no public supplementary material available

Citation

Aster, H.-C., Romanos, M., Walitza, S., Gerlach, M., Mühlberger, A., Rizzo, A., et al. (2022). Responsivity of the striatal dopamine system to methylphenidate: A within-subject I-123-β-CIT-SPECT study in male children and adolescents with attention-deficit/hyperactivity disorder. Frontiers in Psychiatry, 13: 804730. doi:10.3389/fpsyt.2022.804730.

Cite as: https://hdl.handle.net/21.11116/0000-000A-8CA4-F

Abstract

Background: Methylphenidate (MPH) is the first-line pharmacological treatment of attention-deficit/hyperactivity disorder (ADHD). MPH binds to the dopamine (DA) transporter (DAT), which has high density in the striatum. Assessments of the striatal dopamine transporter by single positron emission computed tomography (SPECT) in childhood and adolescent patients are rare but can provide insight on how the effects of MPH affect DAT availability. The aim of our within-subject study was to investigate the effect of MPH on DAT availability and how responsivity to MPH in DAT availability is linked to clinical symptoms and cognitive functioning.

Methods: Thirteen adolescent male patients (9–16 years) with a diagnosis of ADHD according to the DSM-IV and long-term stimulant medication (for at least 6 months) with MPH were assessed twice within 7 days using SPECT after application of I-123-β-CIT to examine DAT binding potential (DAT BP). SPECT measures took place in an on- and off-MPH status balanced for order across participants. A virtual reality continuous performance test was performed at each time point. Further clinical symptoms were assessed for baseline off-MPH.

Results: On-MPH status was associated with a highly significant change (−29.9%) of striatal DAT BP as compared to off-MPH (t = −4.12, p = 0.002). A more pronounced change in striatal DAT BP was associated with higher off-MPH attentional and externalizing symptom ratings (Pearson r = 0.68, p = 0.01). Striatal DAT BP off-MPH, but not on-MPH, was associated with higher symptom ratings (Pearson r = 0.56, p = 0.04).

Conclusion: Our findings corroborate previous reports from mainly adult samples that MPH changes striatal DAT BP availability and suggest higher off-MPH DAT BP, likely reflecting low baseline DA levels, as a marker of symptom severity.